Ticker Symbol: EOLS
Evolus Inc
$7.01 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
United States
Currency:
USD
Asset
Type: Common Stock
CIK:0001570562
Company Profile
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.
Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 520 Newport Center Dr Ste 1200
Website: www.evolus.com
CEO: David Moatazedi
Tags:
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $8.72
Change:
$0.05
(
0.58%)
Days Range: $8.59 - $8.98
Beta: 0.69
52wk. High: $11.49
52wk. Low: $6.51
Ytd. Change 16.02%
50 Day Moving Average: $8.98
200 Day Moving Average: $8.77
Shares Outstanding: 56971563
Valuation
Market Cap: 49.7B
PE Ratio: -7.39
EPS (TTM): -1.18
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A